Alternatives to Schrödinger

DigitalClone®, for Engineering is the only software that integrates multiple scales of analysis into a single package. It is the world's best gearbox reliability prediction tool. DC-E, in addition to the modeling and analysis capabilities at the level of the gearbox and the gear/bearing, is the only software that models fatigue life using detailed, physics-based models (US Patent 10474772B2). DC-E allows the construction of a digital twin of a gearbox. This includes all stages of the asset's lifecycle, from design and manufacturing optimization to supplier selection to failure root cause analysis to condition based maintenance and prognostics. This computational environment reduces the time and cost of bringing new designs to market and maintaining them over time.

SYNTHIA™ Retrosynthesis software, developed by computer scientists and coded by chemists, allows scientists to quickly and easily navigate novel and innovative pathways for novel and previously published target molecules. You can quickly and efficiently scan hundreds pathways to identify the best options for your needs. Discover the most cost-effective route to your target molecule with the latest visualization and filtering features. You can easily customize the search parameters to eliminate or highlight reactions, reagents, or classes of molecules. Explore innovative and unique syntheses to build your desired molecule. Easy to generate a list for starting materials that are commercially available for your synthesis. ISO/IEC 27001 Information Security Certification will guarantee the confidentiality, integrity and protection of your data.

The biopharmaceutical sector today is characterized by its intricacy, driven by increasing demands for enhanced specificity and safety, the emergence of new treatment classes, and the complexity of disease mechanisms. To navigate this intricate landscape, a profound comprehension of therapeutic dynamics is essential. Advanced modeling and simulation techniques offer a distinctive approach to investigate biological and physicochemical phenomena at the atomic scale. This methodology not only informs physical experimentation but also expedites the drug discovery and development phases. BIOVIA Discovery Studio integrates more than three decades of peer-reviewed research with cutting-edge in silico methodologies, including molecular mechanics, free energy assessments, and biotherapeutics developability, all within a unified framework. By equipping researchers with a comprehensive suite of tools, it facilitates a deeper examination of protein chemistry, thereby accelerating the discovery of both small and large molecule therapeutics, from Target Identification all the way through to Lead Optimization. Ultimately, this synergy of research and technology underscores the vital role of innovative tools in transforming biopharmaceutical advancements.

alvaModel is an advanced software application designed for the construction, validation, comparison, and implementation of QSAR and QSPR models. It excels in supporting both regression and classification tasks through the use of molecular descriptors and fingerprints, emphasizing transparency, interpretability, and scientific rigor in its models. This software offers a variety of data splitting techniques, variable selection approaches, and modeling algorithms, as well as thorough internal and external validation methods. Additionally, alvaModel includes diagnostic visualizations, applicability domain evaluations, and tools for model comparison, which aid users in pinpointing reliable and predictive modeling solutions. Crafted in accordance with the highest standards of chemometrics, alvaModel promotes the creation of interpretable models that align with OECD guidelines for QSAR validation, making it ideal for both research and regulatory uses. Its user-friendly graphical interface walks users through the entire modeling process while providing comprehensive control over every aspect of the modeling journey, ensuring a seamless experience. Ultimately, alvaModel stands out as a valuable asset for chemists and researchers aiming to enhance their modeling capabilities.

Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.

LiveDesign serves as an integrated informatics solution that empowers teams to accelerate their drug discovery initiatives through collaborative design, experimentation, analysis, tracking, and reporting on a unified platform. It allows for the collection of innovative ideas alongside experimental and modeling data seamlessly. Users can develop and archive new virtual compounds within a centralized repository, assess them with sophisticated models, and prioritize the most promising designs. By merging biological data and model outputs from various corporate databases, the platform leverages advanced cheminformatics to provide a comprehensive analysis of all information simultaneously, facilitating quicker compound development. The platform employs cutting-edge physics-based methodologies along with machine learning to enhance prediction accuracy significantly. Teams can collaborate in real-time, regardless of location, enabling them to share concepts, conduct tests, make revisions, and progress chemical series while maintaining a clear record of their work. This not only fosters innovation but also ensures that projects remain organized and efficient throughout the drug discovery process.

QSimulate presents an array of quantum simulation platforms that harness the principles of quantum mechanics to address intricate, large-scale challenges in life sciences and materials science. The QSP Life platform introduces innovative quantum-enhanced techniques for drug discovery and optimization, facilitating pioneering quantum simulations of ligand-protein interactions that are relevant throughout the entire computational drug discovery journey. Meanwhile, the QUELO platform enables hybrid quantum/classical free energy calculations, empowering users to conduct relative free energy assessments via the free energy perturbation (FEP) method. Furthermore, QSimulate's advancements enable significant progress in quantum mechanics/molecular mechanics (QM/MM) simulations tailored for extensive protein modeling. In the realm of materials science, the QSP Materials platform opens up quantum mechanical simulations to a broader audience, allowing experimentalists to streamline complex workflows without requiring specialized expertise, ultimately fostering greater innovation in the field. This democratization of technology marks a pivotal shift in how researchers can approach and solve scientific problems.

alvaBuilder is an innovative molecular design software that facilitates the creation of new chemical structures tailored to specific user-defined criteria, including structural, physicochemical, and modeling parameters. This tool allows for the generation of entirely new molecules from the ground up or the modification of existing ones through fragment-based and rule-driven methodologies. Moreover, alvaBuilder harmonizes with QSAR/QSPR workflows, empowering users to influence the molecular generation process through predictive models, ranges of descriptors, and targeted properties. This software is particularly beneficial for medicinal chemistry, lead optimization, and virtual screening endeavors, efficiently navigating chemical space while ensuring both chemical viability and interpretability. Designed for both research and industrial purposes, alvaBuilder is an essential resource for scenarios requiring molecular generation that is transparent, controllable, and reproducible, making it a valuable asset in the field of drug discovery. By providing these capabilities, it enhances the potential for innovative solutions in chemical research and development.

Avogadro serves as a sophisticated molecular editor and visualizer that operates across multiple platforms, catering to fields such as computational chemistry, molecular modeling, bioinformatics, and materials science. With its ability to provide flexible, high-quality rendering alongside a robust plugin architecture, it enhances user experience significantly. This free, open-source tool is compatible with Mac, Windows, and Linux, making it accessible to a wide range of users in scientific disciplines. Its design emphasizes not only functionality but also adaptability to various research needs.

Promethium is an innovative platform for chemistry simulations that harnesses the power of GPUs to significantly speed up the development of drugs and materials by providing more efficient and precise quantum chemistry calculations. Specifically engineered for NVIDIA data center GPUs, such as the A100, it utilizes advanced QC Ware streaming algorithms to deliver remarkable computational speed and impressive power efficiency. This platform can perform density functional theory (DFT) calculations on molecular systems containing as many as 2,000 atoms, enabling researchers to conduct simulations of large molecular structures that traditional CPU-based ab initio methods cannot handle. For example, it can execute a single-point calculation for a protein with 2,056 atoms in just 14 hours using only one GPU. Promethium is equipped with a diverse array of functionalities, including single-point energy computations, geometry optimizations, conformer searches, torsion scans, reaction path optimizations, transition state optimizations, interaction energy evaluations, and relaxed potential energy surface explorations. Its capabilities make it a powerful tool for chemists looking to push the boundaries of molecular modeling and simulation. Ultimately, Promethium is set to transform the landscape of computational chemistry.

Amazon Bio Discovery is an innovative application leveraging AI to enhance the efficiency of early-stage drug discovery by fusing computational biology models with practical laboratory testing in a cohesive "lab-in-the-loop" approach. This tool empowers researchers by granting them immediate access to an extensive library of biological foundation models developed from vast biological datasets, facilitating the rapid generation and assessment of potential drug candidates, including antibodies, with improved accuracy and speed. Additionally, the platform features an integrated AI agent that allows users to engage in natural language conversations to choose suitable models, set up experiments, and fine-tune inputs, eliminating the need for advanced programming skills or complex infrastructure. Researchers can also create multi-step workflows that integrate various models, evaluate their efficacy, and share workflows among teams, thereby fostering better collaboration between computational biologists and laboratory scientists. Ultimately, this powerful tool aims to streamline the drug discovery process and enhance scientific innovation in the field.

Utilize COMSOL's multiphysics software to replicate real-world designs, devices, and processes effectively. This versatile simulation tool is grounded in sophisticated numerical techniques. It boasts comprehensive capabilities for both fully coupled multiphysics and single-physics modeling. Users can navigate a complete modeling workflow, starting from geometry creation all the way to postprocessing. The software provides intuitive tools for the development and deployment of simulation applications. COMSOL Multiphysics® ensures a consistent user interface and experience across various engineering applications and physical phenomena. Additionally, specialized functionality is available through add-on modules that cater to fields such as electromagnetics, structural mechanics, acoustics, fluid dynamics, thermal transfer, and chemical engineering. Users can select from a range of LiveLink™ products to seamlessly connect with CAD systems and other third-party software. Furthermore, applications can be deployed using COMSOL Compiler™ and COMSOL Server™, enabling the creation of physics-driven models and simulation applications within this robust software ecosystem. With such extensive capabilities, it empowers engineers to innovate and enhance their projects effectively.

AIDDISON™ is an innovative drug discovery software that harnesses the capabilities of artificial intelligence (AI), machine learning (ML), and advanced 3D computer-aided drug design (CADD) techniques, serving as an essential resource for medicinal chemistry applications. This comprehensive platform streamlines both ligand-based and structure-based drug design, effectively merging all components necessary for virtual screening while also facilitating in-silico lead discovery and optimization processes. By leveraging these cutting-edge technologies, AIDDISON™ significantly enhances the efficiency and effectiveness of the drug development pipeline.

Rare diseases often lack comprehensive research, resulting in insufficient knowledge about essential elements for an effective drug discovery initiative. Our innovative AI platform, Healnet, addresses these issues by scrutinizing vast amounts of drug and disease data to uncover new connections that may lead to potential treatments. Utilizing cutting-edge technologies throughout the discovery and development process allows us to operate multiple phases simultaneously and on a large scale. The conventional approach of focusing on a single disease, target, and drug is overly simplistic, yet it remains the standard for most pharmaceutical companies. The future of drug discovery is driven by AI, characterized by parallel processes and an absence of rigid hypotheses, fundamentally integrating the three core paradigms of drug discovery into a cohesive strategy. This new paradigm not only enhances efficiency but also fosters creativity in developing solutions for complex health challenges.

DNAnexus Apollo™ enhances the efficiency of precision drug discovery by fostering collaboration that extracts valuable insights from omics data. The process of precision drug discovery involves the aggregation and examination of vast amounts of omics and clinical information. These extensive datasets serve as valuable assets; however, many traditional and custom-built informatics tools struggle to manage their intricacies and scale. Additionally, the effectiveness of precision medicine initiatives can be hindered by fragmented data sources, inadequate collaboration tools, and the challenges posed by complex, evolving regulatory and security demands. By enabling scientists and clinicians to jointly investigate and interpret omics and clinical data within a unified framework, DNAnexus Apollo™ bolsters precision drug discovery efforts. This platform, which is powered by a resilient and scalable cloud infrastructure, facilitates the seamless and secure sharing of data, tools, and analyses among peers and collaborators, regardless of whether they are nearby or across the globe. Ultimately, Apollo not only streamlines the data-sharing process but also enhances the overall collaborative experience in the pursuit of innovative drug discoveries.

BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.

ArgusLab is a program designed for molecular modeling, graphics, and drug design, specifically for Windows platforms. While it may be somewhat outdated, it continues to enjoy a surprising level of popularity with over 20,000 downloads recorded. This software is available under a free license, which means you don't have to fill out any forms to access it. Educators can utilize as many copies as necessary for their classes, allowing students to benefit from ArgusLab’s features. However, it is important to note that redistributing ArgusLab from external websites is prohibited, although linking to the official site from your own is permitted. Currently, there is a modest initiative in progress to adapt ArgusLab for use on the iPad. Additionally, efforts have been made to integrate the Qt cross-platform development environment to potentially expand compatibility across Mac, PC, and Linux systems, enhancing its accessibility for a wider audience. This commitment to adaptability underscores the software's ongoing relevance in the field of molecular modeling.

Founded in 2000, VeraChem LLC aims to enhance the field of computer-aided drug discovery and molecular design by creating advanced computational chemistry techniques that merge innovative basic science with practical applications in research. A key aspect of the company's strategy for product development lies in delivering efficient, high-performance software solutions along with extensive user support. Among the current capabilities of VeraChem's software are predictions for protein-ligand and host-guest binding affinities, rapid and precise calculations of partial atomic charges for drug-like molecules, and the computation of energies and forces utilizing widely-used empirical force fields. Additionally, the software features automatic generation of alternate resonance forms for drug-like compounds, a robust conformational search enabled by the Tork algorithm, and the automatic identification of topological and three-dimensional molecular symmetries. The modular code base of VeraChem’s software packages allows for flexibility and adaptability in meeting diverse research needs, ensuring that users can leverage these tools effectively for their specific applications.

Recursion is a leading TechBio innovator using artificial intelligence to radically improve how new medicines are discovered and developed. The company was founded on the idea that images of cells could be used to train AI systems to understand disease biology at scale. By combining data, machine learning models, and powerful computing, Recursion works to overcome the inefficiencies of traditional drug discovery. Its Recursion OS platform connects massive proprietary biological datasets with automated experimentation and AI-driven insights. This approach has produced a growing pipeline of potential therapies for oncology and rare diseases with high unmet medical needs. Recursion has demonstrated significant gains in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. Strategic partnerships with pharmaceutical companies and technology leaders expand the reach of its platform. The company also collaborates with NVIDIA to power its discovery efforts using BioHive-2, one of the most advanced supercomputers in biopharma. Together, these capabilities position Recursion as a leader in AI-driven drug discovery. Its ultimate goal is to deliver better medicines to patients through precision design and data-driven science.

InSilicoTrials.com is an online platform that offers a user-friendly environment for computational modeling and simulation, featuring a range of integrated, easy-to-navigate in silico tools. It primarily serves professionals in the medical device and pharmaceutical industries. The in silico tools designed for medical devices facilitate computational testing across various biomedical fields, including radiology, orthopedics, and cardiovascular health, during the stages of product design, development, and validation. For the pharmaceutical industry, the platform grants access to in silico tools that support all phases of drug discovery and development across diverse therapeutic areas. We have developed a unique cloud-based platform grounded in crowdscience principles, allowing users to efficiently utilize validated models and reduce their R&D expenses. Additionally, users can explore a continuously expanding catalog of models available for use on a pay-per-use basis, ensuring flexibility and accessibility for their research needs.

Chemical Computing Group (CCG) is well-known for its dedication to collaborative scientific assistance. Operating from locations across North America, Europe, and Asia, our team, comprised of PhD-level scientists, partners closely with clients to deliver personalized support, practical training, and expert scientific guidance on a diverse array of projects. In addition to this, CCG is committed to the ongoing development of innovative technologies, leveraging the expertise of mathematicians, scientists, and software engineers while also engaging in scientific partnerships with our customers to enhance research outcomes. This collaborative approach not only improves client satisfaction but also fosters a culture of innovation within the organization.

Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.

AQChemSim is an innovative cloud-based platform created by SandboxAQ that utilizes Large Quantitative Models (LQMs) based on principles of physics and chemistry to transform the landscape of materials discovery and enhancement. By incorporating techniques such as Density Functional Theory (DFT), Iterative Full Configuration Interaction (iFCI), Generative AI, Bayesian Optimization, and Chemical Foundation Models, AQChemSim facilitates precise simulations of molecular and material dynamics in real-world scenarios. The platform's features allow it to forecast performance under diverse stress conditions, expedite formulation via in silico testing, and investigate eco-friendly chemical processes. Remarkably, AQChemSim has achieved notable progress in battery technology, cutting the prediction time for lithium-ion battery end-of-life by 95%, while also attaining 35 times greater accuracy with a mere fraction of the data previously required. This advancement not only streamlines research but also paves the way for more efficient and sustainable energy solutions in the future.

GPT-Rosalind is an advanced reasoning model created by OpenAI, aimed at enhancing scientific exploration in fields like biology, drug development, and translational medicine. Tailored for workflows in life sciences, it assists researchers in managing extensive literature, experimental findings, and specialized databases to formulate and test innovative concepts. By integrating a profound understanding of disciplines such as chemistry, genomics, protein engineering, and disease biology with sophisticated tool-usage capabilities, it effectively interacts with scientific databases, examines experimental results, and facilitates intricate, multi-stage reasoning tasks. Its functionalities span evidence synthesis, hypothesis formulation, literature assessment, sequence analysis, and experimental design, empowering scientists to transition more swiftly from raw data to meaningful insights. Furthermore, GPT-Rosalind revolutionizes cumbersome, time-consuming research methodologies into streamlined, AI-enhanced workflows, ultimately fostering a more productive scientific environment. This model exemplifies the fusion of artificial intelligence with scientific inquiry, paving the way for groundbreaking discoveries.

Makya stands out as the pioneering user-centric SaaS platform dedicated to AI-enhanced de novo drug design, particularly emphasizing Multi-Parametric Optimization (MPO). This innovative tool empowers users to create novel and easily synthesize compounds based on a multi-objective framework, achieving unprecedented levels of speed, efficiency, and variety. Makya incorporates a range of generative algorithms tailored to various stages of drug development, from hit discovery to lead optimization; it includes a fine-tuning generator for pinpointing ideal solutions within your specified chemical landscape, a novelty generator designed to explore fresh concepts for re-scaffolding and hit discovery, and a forward generator to create a targeted library of compounds that can be readily synthesized from commercially available starting materials. The recently introduced Makya 3D module significantly improves both the user interface and the scientific capabilities of the platform. With a comprehensive array of 3D modeling functionalities available for both ligand-based and structure-based approaches, Makya 3D allows for the calculation of 3D scores, which can be seamlessly utilized to guide compound generation within the platform. This integration not only enhances the design process but also offers researchers deeper insights into their molecular designs.

Scitara DLX™ provides a swift connectivity framework suitable for any instrument found within life science laboratories, all while operating on a cloud-based platform that is both compliant and auditable. As a versatile digital data infrastructure, Scitara DLX™ facilitates connections between various instruments, resources, applications, and software utilized in the lab. The comprehensive cloud system ensures that all data sources are interconnected, promoting seamless data movement across numerous endpoints. Consequently, researchers can concentrate on their scientific endeavors instead of being bogged down by data-related challenges. Moreover, DLX intelligently curates and corrects data as it is processed, fostering the creation of accurate and well-organized data models that are essential for enhancing AI and ML systems. This robust approach plays a vital role in advancing digital transformation strategies within the pharmaceutical and biopharmaceutical sectors. By unlocking valuable insights from scientific data, the platform accelerates decision-making processes in drug discovery and development, ultimately aiding in the expedited launch of new medications into the market. Additionally, the integration of such a sophisticated infrastructure not only streamlines workflows but also enhances collaboration among researchers, paving the way for innovative solutions in the life sciences field.

Eidogen-Sertanty's Target Informatics Platform (TIP) stands out as the pioneering structural informatics system and knowledgebase that empowers researchers to explore the druggable genome through a structural lens. By harnessing the burgeoning wealth of experimental protein structure data, TIP revolutionizes structure-based drug discovery, shifting it from a limited, low-throughput field to a dynamic and data-rich scientific discipline. It is specifically designed to connect the realms of bioinformatics and cheminformatics, providing drug discovery scientists with a repository of insights that are not only unique but also highly synergistic with the information available from traditional bio- and cheminformatics tools. The platform's innovative combination of structural data management with advanced target-to-lead calculation and analytical capabilities significantly enhances every phase of the drug discovery process. With TIP, researchers are better equipped to navigate the complexities of drug development and make informed decisions.

BioNeMo is a cloud service and framework for drug discovery that leverages AI, built on NVIDIA NeMo Megatron, which enables the training and deployment of large-scale biomolecular transformer models. This service features pre-trained large language models (LLMs) and offers comprehensive support for standard file formats related to proteins, DNA, RNA, and chemistry, including data loaders for SMILES molecular structures and FASTA sequences for amino acids and nucleotides. Additionally, users can download the BioNeMo framework for use on their own systems. Among the tools provided are ESM-1 and ProtT5, both transformer-based protein language models that facilitate the generation of learned embeddings for predicting protein structures and properties. Furthermore, the BioNeMo service will include OpenFold, an advanced deep learning model designed for predicting the 3D structures of novel protein sequences, enhancing its utility for researchers in the field. This comprehensive offering positions BioNeMo as a pivotal resource in modern drug discovery efforts.

AQBioSim is an innovative cloud-based platform created by SandboxAQ that utilizes Large Quantitative Models (LQMs) based on principles of physics and chemistry to transform the processes of material discovery and optimization. By combining techniques such as Density Functional Theory (DFT), Iterative Full Configuration Interaction (iFCI), Generative AI, Bayesian Optimization, and Chemical Foundation Models, AQBioSim facilitates highly accurate simulations of molecular and material behaviors in real-world scenarios. Among its numerous features, AQBioSim can predict performance under various stressors, enhance formulation processes through in silico testing, and investigate eco-friendly chemical methods. A standout achievement of AQBioSim lies in its remarkable progress in battery technology, where it has cut the time needed for lithium-ion battery end-of-life predictions by an astonishing 95%, while also attaining 35 times greater accuracy using only 50 times less data. This platform thus not only accelerates material innovation but also significantly contributes to advancements in sustainable energy solutions.

To reduce attrition rates for molecular entities that are unlikely succeed in nomination as drug candidates, direct new compound synthesizers, and focus animal testing requirements, calculate drug toxicity and safety.

Microsoft Discovery is an advanced AI-powered platform designed to accelerate scientific discovery by enabling researchers to collaborate with a team of specialized AI agents. This platform leverages a graph-based knowledge engine that connects diverse scientific data, allowing for deep, contextual reasoning over complex and often contradictory theories. Researchers can customize AI agents to align with their specific domains and tasks, making it easier to manage and orchestrate research efforts. Built on Microsoft Azure, Discovery ensures a high level of trust, transparency, and compliance, offering an enterprise-ready solution. The platform has already been used to accelerate the development of a novel coolant for data centers, cutting the discovery time from months to just 200 hours. This demonstrates the transformative potential of AI in R&D, providing researchers with the tools to unlock new possibilities and innovations at scale.

AI-powered drug discovery is a proven technology. Cerella extracts hidden insights from your drug discovery data to reveal the best compounds and most valuable experiment for your project. It can make confident predictions by accurately filling in the missing values. This is especially useful for expensive downstream experiments, which are impossible to predict using other methods. This allows you to do more with sparse and limited data sets.

CDD Vault allows you to intuitively organize chemical structures, biological study data, as well as collaborate with external or internal partners via a simple web interface. Start a free trial to see how easy it can be to manage drug discovery data. Tailored for You Affordable Scales with your project team Activity & Registration * Electronic Lab Notebook * Visualization * Inventory * APIs

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. More than 2 million scientists and 10,000 customers trust Dotmatics to accelerate research and help make the world a healthier, cleaner, and safer place to live.

We have established ourselves as frontrunners in the fields of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology, a status achieved through the achievements our clients have experienced while partnering with us. Leveraging over two decades of expertise, our skilled team excels at transforming complex scientific concepts into accessible software solutions, while also offering specialized consulting services that bolster drug discovery, clinical development research, and regulatory submission processes. Our dedication to client success drives our continuous improvement and innovation in these critical areas.

Clara provides specialized tools and pre-trained AI models that are driving significant advancements across various sectors, such as healthcare technologies, medical imaging, pharmaceutical development, and genomic research. Delve into the comprehensive process of developing and implementing medical devices through the Holoscan platform. Create containerized AI applications using the Holoscan SDK in conjunction with MONAI, and enhance deployment efficiency in next-gen AI devices utilizing the NVIDIA IGX developer kits. Moreover, the NVIDIA Holoscan SDK is equipped with acceleration libraries tailored for healthcare, alongside pre-trained AI models and sample applications designed for computational medical devices. This combination of resources fosters innovation and efficiency, positioning developers to tackle complex challenges in the medical field.

Since its inception in 1985, ChemDraw® solutions have delivered exceptional features and integrations that allow users to swiftly convert their concepts and sketches into impressive publications. ChemOffice+ Cloud serves as a comprehensive suite for chemistry communication, transforming chemical illustrations into valuable knowledge by streamlining the management, reporting, and presentation of chemistry research. This powerful suite is specifically designed to enhance and expedite communication within the field of chemistry. Building upon the foundation of ChemDraw Professional, ChemOffice+ Cloud offers a wide range of advanced tools that support scientific inquiry and collaboration. The once tedious process of drafting reports for chemical research is now significantly more efficient thanks to ChemOffice+ Cloud. With its robust capabilities for searching, reusing, selecting, and organizing chemical structures and data, chemists can effortlessly create polished PowerPoint presentations and manuscripts, making their work more accessible and impactful. This transformation not only saves time but also elevates the overall quality of research dissemination in the scientific community.

3decision® serves as a cloud-based repository for protein structures, focusing on efficient management of structural data and offering sophisticated analytics to support teams involved in the discovery of small molecules and biologics, thereby expediting the process of structure-based drug design. The platform consolidates and standardizes both experimental and computational protein structures sourced from publicly available databases such as RCSB PDB and AlphaFoldDB, in addition to proprietary datasets, and accommodates formats like PDBx/mmCIF and ModelCIF. This comprehensive approach guarantees seamless access to a variety of structural formats including X-Ray, NMR, cryo-EM, and modeled structures, thereby promoting collaboration and bolstering research initiatives. In addition to its storage capabilities, 3decision® enhances each entry with valuable metadata and sequence information, which encompasses details on protein-ligand interactions, antibody annotations, and specifics about binding sites. Equipped with advanced analytical instruments, the platform is capable of pinpointing druggable sites, evaluating off-target risks, and facilitating comparisons of binding sites, which collectively transform extensive structural datasets into practical insights that can drive research forward. Furthermore, its cloud-based architecture fosters enhanced collaboration among research teams, making it easier for scientists to share findings and insights, ultimately leading to more innovative approaches in drug discovery and development.

ExoMatter is revolutionizing the traditionally tedious and expensive process of materials research and development by harnessing advanced AI technologies and data-mining capabilities. The platform offers a tailored selection of the most appropriate materials for your specific needs. By integrating data from various scientific repositories and your own datasets, ExoMatter enhances this information through AI, enabling you to evaluate a diverse array of multidimensional physical, chemical, and engineering factors, alongside sustainability concerns and projected costs. Our commitment to using scientific materials data aims to identify superior and more eco-friendly materials. With our innovative materials research platform, you can swiftly navigate through millions of materials, using AI-driven tools that not only enrich the data but also provide you with comprehensive control over your selection criteria. Leverage ExoMatter’s unique scoring and ranking system to compile a refined list of materials that best suit your application, ensuring that you make informed and efficient choices in your materials selection process. This approach not only streamlines your research efforts but also significantly enhances the overall quality and sustainability of your material choices.

Kebotix is a pioneering technology platform focused on the development of new chemicals and materials, heralding a transformative era of rapid innovation through the integration of artificial intelligence and robotic automation. The company has introduced the world's first autonomous laboratory dedicated to materials discovery, driven by AI and robotics, which revolutionizes traditional research methods. By greatly enhancing the exploration, discovery, utilization, and production of novel molecules and materials, Kebotix aims to address some of the most pressing challenges faced globally. Collaborate with us to expedite the market introduction of your products while leveraging our cutting-edge material design technologies that are enabled by our self-driving lab. Kebotix propels your research and development efforts into the new digital frontier by offering tailored enterprise AI solutions specifically designed for materials discovery. With our automated learning system that improves with each cycle of predict-produce-prove, we empower you to deliver superior products to market more swiftly than ever before. This innovative approach not only saves time but also significantly enhances the efficiency of the research process.

BC platforms harnesses cutting-edge scientific advancements, innovative technological capabilities, and strategic alliances to transform drug discovery and tailor healthcare solutions. Our platform is modular and highly adaptable, designed for integrating healthcare data effectively. With an open analytics framework, we seamlessly merge the most recent innovative methods and technology advancements into a single, cohesive platform. We prioritize security, holding ISO 27001 certification alongside compliance with GDPR and HIPAA regulations. Our comprehensive product suite empowers a contemporary healthcare system to fully adopt personalized medicine approaches. Our scalable deployment options support everything from initial setups to expansive healthcare operations. By offering a unique end-to-end toolbox, we facilitate the expedited application of research findings in clinical settings. Moreover, we strive to minimize your risks, enhance the value of your pipeline, and advance your enterprise data strategy by overcoming data access challenges and enabling swift insights. In doing so, we aim to foster a health ecosystem that is both responsive and forward-thinking.

DIGIMU® creates digital polycrystalline microstructures that accurately reflect the material's heterogeneities, ensuring compliance with the intricate topological features of the microstructure. The boundary conditions applied to the Representative Elementary Volume (REV) mimic the experiences of a material point at the macroscopic level, particularly during the thermomechanical cycles relevant to that specific point. Utilizing a Finite Element formulation, the software simulates the various physical phenomena occurring in metal forming processes, such as recrystallization, grain growth, and Zener pinning caused by second phase particles. To enhance digital accuracy and minimize computation times, DIGIMU® employs advanced automated anisotropic meshing and remeshing adaptation technology, which allows for a detailed representation of grain boundaries while optimizing the number of elements used. This innovative approach not only streamlines the computational process but also improves the reliability of the simulations, making it a powerful tool for material scientists.

Alchemite specializes in AI-enhanced physical modeling and offers solutions that assist organizations in deriving actionable insights from both experimental and simulation data, merging machine learning techniques with physics-informed models to enhance prediction accuracy, decrease experimental expenses, and streamline product and process development. Their offerings encompass a variety of domains, including materials discovery and design, predictive modeling for performance and reliability, multiscale modeling that bridges atomic and macroscopic behavior, as well as the automation of various workflow tasks such as data integration, surrogate modeling, and model validation. Furthermore, they advocate for physics-aware neural networks and hybrid modeling strategies that adhere to fundamental scientific principles while simultaneously learning from data, leading to quicker and more precise simulations, a diminished need for costly physical testing, and better-informed decision-making processes. Intellegens' tools find applications in various fields, including the prediction of battery performance and optimization of chemical processes, showcasing their versatility and effectiveness in addressing complex challenges. By integrating advanced computational methodologies, Alchemite aims to empower organizations to innovate and achieve their goals more efficiently.

The process of introducing a new medication to the market, starting from initial development to the final launch, is both time-intensive and heavily regulated, often spanning over a decade or more. Achieving success in this endeavor hinges on the timely availability of precise analytical data, which is essential for making informed decisions during the early stages of development and reducing the likelihood of setbacks later on. Modern drug development primarily follows a systematic approach, with the crucial first step usually being the identification of a biological target to concentrate efforts on. This target identification demands a comprehensive understanding of the characteristics of the candidates, enabling swift and reliable identification of the most promising options. After establishing a biological target, the next significant hurdle is identifying the most advantageous lead molecules, which entails discovering potential drug candidates—these may include small organic compounds or biological constructs with therapeutic capabilities. Thus, the entire journey from concept to market is a complex interplay of scientific insight and strategic decision-making.